uniQure N.V. Ordinary Shares vs Vishay Intertechnology Inc. Common Stock — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while Vishay Intertechnology Inc. Common Stock trades at $27.88 (market cap $4.87B). The key difference: Vishay Intertechnology Inc. Common Stock is far larger — about 3.3× uniQure N.V. Ordinary Shares's market cap, and Vishay Intertechnology Inc. Common Stock pays a 1.26% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Vishay Intertechnology Inc. Common Stock for 6 Days on average.
| QURE | VSH | |
|---|---|---|
Market Cap | $1.48B | $4.87B |
Volume | 2,488,780 | 2,805,188 |
Sector | Health | Technology |
52-Week High | $70.59 | $64.90 |
52-Week Low | $9.03 | $11.82 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $728.62M | $4.67B |
Dividend Yield | — | 1.26% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vishay Intertechnology (VSH) trades at $31.76, down 0.84% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a high P/E ratio of 158.8 but improving profitability trends, with net income projected to turn positive in 2026. Recent news highlights the company's focus on EV and AI infrastructure solutions, positioning it for growth in key technology markets.
While analyst consensus remains positive with a $43 price target, investors face valuation concerns and execution risks. The technical outlook suggests near-term pressure, but long-term growth potential exists if the company can capitalize on automotive and AI semiconductor demand while improving profit margins from current low levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →Vishay Intertechnology manufactures discrete semiconductors and passive electronic components. Its products include diodes, MOSFETs, resistors, capacitors, and sensors.
Read more on VSH →